Institutional Career Development Core

宾夕法尼亚州立大学的机构职业发展核心旨在继续专注于招聘、培训和培育 走向独立是临床翻译科学(CTS)学科的新一代。宾夕法尼亚大学的KL2 该计划还为初级教师提供全面的研究培训和职业发展经验 随着博士后学者过渡到医学、牙科、护理学院的初级教员， 工程学和兽医。该计划包括：(I)结构化课程，可选择 硕士或证书课程，(2)个性化团队研究指导，(3)职业发展教育 以专业技能发展方案的形式，(4)为获得K和 R奖励和试点赠款，(5)额外的学习环境，包括系列研讨会、专题讨论会、 多学科选修课和实习生/校外奖学金，以及(Vi)进入核心课程 旨在解决CTS基础设施障碍的资源。在完成KL2计划后，学者们 将掌握CTS科学家所需的核心能力，已在同行评议中发表 文学，获得资助，和/或继续参与CTS的学术或行业任命。 我们在这个周期的努力将继续集中在加强CTS协作团队的纪律上 科学方法。每年将任命9名学者，每人至少为期两年。 我们的目标是： 1.(1)继续提供发现科学、创业科学和监管科学方面的CTS培训机会， 转化治疗学和生物医学信息学，(Ii)扩大到在数据中包括教育机会- 和实施科学和医疗创新，以及(Iii)培训学者利用大数据 以有针对性的精确度处理假设。 2.扩大我们的专业技能发展计划，使学者能够执行长期愿景和 掌握人际关系和职业发展技能。 3.利用宾夕法尼亚大学的创新环境和药物开发的成功来增加更多的机会 让学者们成功地参与到学术和产业的交界处。 4.测试创新战略，以加强CTS工作人员的留用、多样性和包容性。 我们还将吸收新冠肺炎与社区卫生服务相关的经验教训，包括药物治疗方法的变化 以及疫苗开发、评估和监管以及同意、远程医疗和 解除封锁。

Penn’s Institutional Career Development Core aims to continue to focus on recruiting, training, and nurturing towards independence a new generation in the discipline of clinical translational science (CTS). Penn’s KL2 program offers a comprehensive research training and career development experience for junior faculty as well as postdoctoral scholars transitioning to junior faculty in the Schools of Medicine, Dentistry, Nursing, Engineering, and Veterinary Medicine. The program comprises (i) structured curricula with the option of a Master’s degree or certificate program, (ii) individualized team research mentoring, (iii) career-building education in the form of a Professional Skills Development Program, (iv) infrastructural support in the acquisition of K and R awards and pilot grants, (v) additional learning environments inclusive of seminar series, symposia, multidisciplinary electives, and intern-/externships at the academic-industrial interface, and (vi) access to core resources designed to address infrastructural barriers to CTS. Upon completion of the KL2 program, scholars will have mastered the required core competencies for CTS scientists, have published in peer-reviewed literature, received grant funding, and/or an academic or industry appointment with continued CTS engagement. Our efforts for this cycle will continue to focus on strengthening the discipline of CTS in a collaborative team science approach. Nine scholars will be appointed per year, each for a minimum of two years. Our objectives are: 1. (i) To continue to provide CTS training opportunities in discovery-, entrepreneurial- , and regulatory science, translational therapeutics, and biomedical informatics, (ii) To expand to include educational opportunities in data- and implementation science and healthcare innovation, and (iii) To train scholars to leverage big data in order to address hypotheses with targeted precision. 2. To expand our Professional Skills Development Program to enable scholars to execute a long-term vision and master interpersonal and professional development skills. 3. To leverage Penn’s innovative environment and drug development successes to increase further opportunities for scholars to engage successfully at the academic-industry interface. 4. To test innovative strategies to enhance retention, diversity and inclusion in the CTS workforce. We will also incorporate lessons from COVID-19 of relevance to CTS including changes in approaches to drug and vaccine development, assessment and regulation and ethical issues of consent, remote healthcare and release from lockdown.